UNSPSC 51182709: Metformin/sitagliptin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182709 Metformin/sitagliptin is a Commodity code that in practice does not map to recent state and local solicitation activity. The code nominally describes a specific combination pharmaceutical (metformin paired with sitagliptin, used in diabetes management), but the two recent opportunities tagged under it involve naloxone procurement and direct-to-manufacturer prescription program design — neither of which relates to the code's stated scope. The mismatch suggests either persistent miscoding in source systems or an alignment issue between the UNSPSC taxonomy and how issuing bodies currently tag pharmaceutical and health-services solicitations.

The two posted opportunities originate from different jurisdictional tiers and geographies but neither involves the metformin/sitagliptin product line. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs for self-insured employee and retiree plans, with no formal award value or timeline specified at that exploratory stage. Both solicitations address pharmaceutical or pharmacy-related needs, but neither procures the specific combination product this code describes. Firms pursuing diabetes-management pharmaceutical contracts may find this code unreliable for opportunity discovery; a search strategy should instead monitor state pharmacy benefit program solicitations, health department drug procurement notices, and managed Medicaid vendor RFPs under broader pharmaceutical supply codes.